Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

Main inclusion criteria include: * Histologically proven, metastatic or locally advanced non resectable, or recurrent post-surgery GIST * Naïve patient or patient previously treated with imatinib as neoadjuvant/adjuvant who relapsed after imatinib discontinuation * c-Kit (CD117) positive tumours detected by immuno-histochemically or PDGFR positive if c-Kit negative Main exclusion criteria include: * Patient previously treated by tyrosine kinase inhibitors except imatinib in case of inclusion criteria * Patient treated for a cancer other than GIST within 5 years before enrolment, with the exception of basal cell carcinoma or cervical cancer in situ * Patient with active central nervous system (CNS) metastasis or with history of CNS metastasis